HAWK与HARRIER:brolucizumab治疗新生血管性年龄相关性黄斑变性的3期随机双盲多中心试验
HAWK和HARRIER是两项设计相似的双盲、多中心、活性对照、随机3期试验,共纳入1817例未治疗的nAMD患者,比较brolucizumab(3 mg或6 mg)与aflibercept 2 mg的疗效与安全性。第48周时brolucizumab在BCVA变化上非劣于aflibercept,超过50%的6 mg组维持q12w给药,解剖学结局优于aflibercept,安全性总体相似。
要点
- 第48周brolucizumab在BCVA变化上非劣于aflibercept。
- 6 mg组超过50%维持q12w给药至第48周。
- brolucizumab解剖学结局(CST下降、视网膜积液)优于aflibercept。
核心结论
- brolucizumab在第48周视力功能上非劣于aflibercept,超过50%的6 mg治疗眼维持q12w给药间隔,解剖学结局优于aflibercept,总体安全性与aflibercept相似。
研究设计与样本
- HAWK和HARRIER为双盲、多中心、活性对照、随机3期试验,共纳入1817例研究眼为未治疗活动性nAMD相关脉络膜新生血管的患者。
- 患者随机接受玻璃体内brolucizumab 3 mg(仅HAWK)或6 mg或aflibercept 2 mg,负荷期3次每月注射后brolucizumab组q12w并视疾病活动调整为q8w,aflibercept组q8w。
主要发现
- 第48周BCVA自基线变化最小二乘均值:HAWK中brolucizumab 6 mg +6.6字母、3 mg +6.1字母 vs aflibercept +6.8字母;HARRIER中6 mg +6.9字母 vs aflibercept +7.6字母,各比较P < 0.001。
- 第48周维持q12w给药的患者比例在brolucizumab 6 mg组为HAWK 56%、HARRIER 51%。
- 第16周相同暴露后疾病活动眼比例:HAWK中brolucizumab 6 mg 24.0% vs aflibercept 34.5%(P = 0.001);HARRIER中22.7% vs 32.2%(P = 0.002)。
- 第48周CST自基线下降最小二乘均值:HAWK中brolucizumab 6 mg -172.8 μm vs aflibercept -143.7 μm(P = 0.001);HARRIER中-193.8 μm vs -143.9 μm(P < 0.001)。
- 解剖学视网膜积液结局有利于brolucizumab优于aflibercept,brolucizumab与aflibercept总体不良事件率大致相似。
关键数值与推荐
- 主要假设为第48周BCVA自基线变化最小二乘均值非劣效,非劣效界值为4字母。
- brolucizumab 6 mg组第48周维持q12w给药比例在HAWK为56%、HARRIER为51%。
临床怎么用
- brolucizumab 6 mg可作为nAMD抗VEGF治疗选择,部分患者可维持q12w给药并减少注射频率。
- 治疗中需根据疾病活动调整brolucizumab给药间隔至q8w。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Two similarly designed phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (nAMD). DESIGN: Double-masked, multicenter, active-controlled, randomized trials. PARTICIPANTS: Patients (N = 1817) with untreated, active choroidal neovascularization due to age-related macular degeneration in the study eye. INTERVENTION: Patients were randomized to intravitreal brolucizumab 3 mg (HAWK only) or 6 mg or aflibercept 2 mg. After loading with 3 monthly injections, brolucizumab-treated eyes received an injection every 12 weeks (q12w) and were interval adjusted to every 8 weeks (q8w) if disease activity was present; aflibercept-treated eyes received q8w dosing. MAIN OUTCOME MEASURES: The primary hypothesis was noninferiority in mean best-corrected visual acuity (BCVA) change from baseline to Week 48 (margin: 4 letters). Other key end points included the percentage of patients who maintained q12w dosing through Week 48 and anatomic outcomes. RESULTS: At Week 48, each brolucizumab arm demonstrated noninferiority to aflibercept in BCVA change from baseline (least squares [LS] mean, +6.6 [6 mg] and +6.1 [3 mg] letters with brolucizumab vs. +6.8 letters with aflibercept [HAWK]; +6.9 [brolucizumab 6 mg] vs. +7.6 [aflibercept] letters [HARRIER]; P < 0.001 for each comparison). Greater than 50% of brolucizumab 6 mg-treated eyes were maintained on q12w dosing through Week 48 (56% [HAWK] and 51% [HARRIER]). At Week 16, after identical treatment exposure, fewer brolucizumab 6 mg-treated eyes had disease activity versus aflibercept in HAWK (24.0% vs. 34.5%; P = 0.001) and HARRIER (22.7% vs. 32.2%; P = 0.002). Greater central subfield thickness reductions from baseline to Week 48 were observed with brolucizumab 6 mg versus aflibercept in HAWK (LS mean -172.8 μm vs. -143.7 μm; P = 0.001) and HARRIER (LS mean -193.8 μm vs. -143.9 μm; P < 0.001). Anatomic retinal fluid outcomes favored brolucizumab over aflibercept. Overall, adverse event rates were generally similar with brolucizumab and aflibercept. CONCLUSIONS: Brolucizumab was noninferior to aflibercept in visual function at Week 48, and >50% of brolucizumab 6 mg-treated eyes were maintained on q12w dosing interval through Week 48. Anatomic outcomes favored brolucizumab over aflibercept. Overall safety with brolucizumab was similar to aflibercept (ClinicalTrials.gov; NCT02307682, NCT02434328).
引用
- Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2019. PMID: 30986442. doi:10.1016/j.ophtha.2019.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。